Dernière mise à jour : 15 août 2026
Today we are going to talk about MRI of the prostate. As I have often explained when discussing prostate cancer, this disease is frequently limited in aggressiveness. The story usually begins with a rising Prostate-Specific Antigen (PSA) blood test from a routine health check-up, which brings the patient to a urology clinic to weigh the pros and cons of a tissue biopsy and, ultimately, to reach a diagnosis. The important question is this: does every man with a suspicious PSA really need a biopsy? The answer is very often no — and here is the evidence behind that.

Autopsy studies of men who died of unrelated causes have long shown that a substantial proportion of older men are walking around with prostate cancer that never troubled them in life — and that a large share of those cancers are low-grade disease that would never have required treatment. In other words, finding a cancer is not the same as finding a cancer worth treating.

This matters because a needle biopsy of the prostate is not a trivial procedure. It can cause blood in the urine, blood in the stool, blood in the semen, and — uncommonly but importantly — a serious bloodstream infection. In the PROMIS study, close to 6% of participants reported a serious adverse event, including eight cases of sepsis.
When a biopsy is genuinely necessary, it should absolutely be done. The real challenge is knowing how to avoid the unnecessary ones. This is where MRI of the prostate has become an essential tool for urologists. Here are its main advantages and limitations.
Advantages of prostate MRI
- It is a non-invasive imaging test that provides a great deal of detail about the anatomy of the prostate gland.
- It is far more sensitive than a blind biopsy. In the PROMIS study, multiparametric MRI detected 93% of clinically significant cancers, compared with just 48% for standard transrectal ultrasound-guided biopsy.
- A negative scan is reassuring. PROMIS reported a negative predictive value of 89% for clinically significant cancer, which is what makes MRI usable as a triage test before biopsy.
- It lets many men skip the biopsy altogether. PROMIS estimated that using MRI to triage would allow about 27% of men to avoid a primary biopsy; in the PRECISION trial, 28% of men in the MRI arm had a scan that was not suspicious and were not biopsied at all.
- When a biopsy is needed, targeting finds more of the cancers that matter. In PRECISION, MRI-targeted biopsy diagnosed clinically significant cancer in 38% of men versus 26% with standard biopsy — using a median of only 4 cores instead of 12.
- It reduces overdiagnosis. PRECISION also found 13 percentage points fewer diagnoses of clinically insignificant cancer in the MRI-targeted group — fewer men labelled with a cancer that was never going to harm them.

Limitations of prostate MRI
- It is expensive compared with conventional ultrasound.
- It is not very specific. In PROMIS, specificity was only 41% and the positive predictive value 51% — meaning a suspicious-looking area is roughly a coin flip, and a scan that looks abnormal still has to be confirmed by biopsy.
- Some scanners require an endorectal coil to be placed in the rectum to improve image quality, which many men find uncomfortable.
- A negative scan is reassuring, not a guarantee. A small number of significant cancers are still missed, which is why men with a negative MRI need continued PSA follow-up rather than simple discharge.
Few diagnoses cause as much anxiety as suspected prostate cancer, and I hope this article helps you understand your options more clearly. If you have further questions, please discuss them with a urologist you trust.
Where imaging and biopsy do confirm significant cancer, surgery is often the definitive answer. Learn about da Vinci prostate cancer surgery and what recovery realistically involves.
If you have an elevated PSA and would like an MRI prostate evaluation before considering a biopsy, Dr. Soarawee Weerasopone offers specialist consultations at Bangkok Hospital Headquarters. Prendre rendez-vous.
Frequently Asked Questions about MRI Prostate
What is an MRI prostate used for?
An MRI prostate is a non-invasive imaging tool used to evaluate the prostate gland in men with elevated PSA levels. It helps urologists identify suspicious areas that may indicate aggressive prostate cancer and decide whether a biopsy is necessary, reducing unnecessary invasive procedures.
How accurate is MRI prostate in detecting cancer?
In the PROMIS study, multiparametric MRI detected 93% of clinically significant prostate cancers, compared with 48% for standard transrectal ultrasound-guided biopsy, with a negative predictive value of 89%. Its weakness is specificity, which was 41%, so a suspicious scan still needs biopsy confirmation. In the PRECISION trial, MRI-targeted biopsy diagnosed clinically significant cancer in 38% of men versus 26% with standard biopsy.
Can MRI prostate replace prostate biopsy?
No, MRI prostate cannot fully replace biopsy. If MRI shows suspicious findings, a biopsy is still required to confirm the diagnosis. However, MRI can spare a large number of men the procedure entirely: PROMIS estimated that around 27% of men could avoid a primary biopsy, and in PRECISION 28% of men in the MRI arm had a non-suspicious scan and were not biopsied.
What are the disadvantages of MRI prostate?
MRI prostate is more expensive than standard ultrasound, and it has limited specificity — 41% in the PROMIS study — so abnormal scans often turn out not to be significant cancer. In some cases an endorectal coil must be inserted into the rectum to improve image quality, which can be uncomfortable. It is also not a definitive diagnostic test, so a biopsy is still needed when findings are suspicious, and a small number of significant cancers can be missed.
Who should consider getting an MRI prostate?
Men with elevated PSA levels, an abnormal digital rectal examination, or a previous negative biopsy but ongoing clinical suspicion for prostate cancer are the best candidates for MRI prostate. Your urologist will assess your individual situation and recommend the most appropriate imaging strategy.
Références
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. PubMed
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med. 2018;378(19):1767–1777. PubMed
Avis de non-responsabilité : Ce contenu est rédigé et revu par le Dr Soarawee Weerasopone, urologue certifié au siège de Bangkok Hospital. Il est destiné uniquement à des fins éducatives et ne constitue pas un avis médical. Consultez toujours un professionnel de la santé qualifié avant de commencer tout traitement médical.
Rédigé et révisé par des médecins : Dr Soarawee Weerasopone (Dr Pom) — Urologue certifié, siège social de l'hôpital de Bangkok, en pratique urologique depuis 2016. Fellowship : Chirurgie robotique, Chang Gung Memorial Hospital, Taïwan (2019) · Stage d'observation : Endourologie, Hôpital universitaire Juntendo, Tokyo (2022) · Chercheur et observateur clinique, Département d'urologie Scott, Baylor College of Medicine, États-Unis (2025-2026).

Le Dr Soarawee Weerasopone (Dr Pom) est urologue certifié au Bangkok Hospital Headquarters, spécialisé en santé masculine, chirurgie robotique (da Vinci Xi) et traitement des calculs rénaux. Il est actuellement chercheur et observateur clinique au département d'urologie Scott du Baylor College of Medicine (2025-2026), sous la direction du Pr Mohit Khera. Il a effectué un fellowship en chirurgie robotique au Chang Gung Memorial Hospital de Taïwan (2019) et un stage d'observation en endourologie au Juntendo University Hospital de Tokyo (2022).


Une réponse